In last week's newsletter, I highlighted how the more liquid stocks in TW's universe had rallied. I also speculated that there is the potential for catch up in the names that didn't rally. Quite simply, if I'm correct on...
Late last year, DriveItAway terminated their relationship with HyreCar (HYRE). DriveItAway had been seen as an important driver of HyreCar’s dealer business, which has been expanding rapidly. The termination of their relationship left an apparent void in that piece...
On Thursday January 24th, Anixa Biosciences held an investor update call. In the preview to the call, management had talked about 2019 being a "transformative" year for the Company. Based on their conference call, if they deliver on their...
Dyadic is a name that we have covered in the past here at Tailwinds. When we last looked at it, the story was one of a great value play with a massive potential upside (Here's the link to our...
~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to be shared. Thank you. ~ Yesterday we initiated a new position in BioVie, Inc. (BIVI). The...
Tailwinds' Take: this is a very positive step for Anixa as it insures that they have rights to this treatment as a platform for multiple solid tumor cancers. If this CAR-T is successful, it will potentially be the first...
MEDFORD, N.Y., May 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in...
Tailwinds' Take: excited to see balance sheet risk off the table for a while here, although the terms of this financing were very steep for current shareholders. With a clear runway, the stock should be driven by the fundamentals,...
Operator:Good day, everyone. Welcome to today’s corporate update and discussion of recent alliance with Cleveland Clinic on breast cancer vaccine. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask...
Tailwinds' Take: more excellent results for this product. It's several years from market, but the data so far suggests it could be on a smooth path through the FDA and the end market is potentially in the billions with...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.